Click the icons below to search through Pioneer’s reports and documents.
|Version||1 Previous versions|
|Date added||April 6, 2021|
|Category||Health Care, Life Sciences, White Papers|
Author: William Smith
Date: April 6, 2021
This report examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. It reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.